Skip to main content
. 2015 May 14;8:51. doi: 10.1186/s13045-015-0149-x

Fig. 1.

Fig. 1

Pattern of PSA and WBC values following sipuleucel-T treatment. Solid arrows: initial APC8015-2 (investigational form of sipuleucel-T produced using 2 μg/mL of PA2024) in December 2010 and subsequent treatment with commercial sipuleucel-T (using 10 μg/mL of PA2024) in December 2012. Open arrows: other therapies. Solid line: PSA prostate-specific antigen; Dotted line: WBC white blood cell count